Company Profile

Vaccinex Inc (AKA: Vaccinex LP)
Profile last edited on: 4/28/2022      CAGE: 1J6F3      UEI: W9DSMAL2EES8

Business Identifier: Novel therapeutic antibodies for neurodegenerative disorders and oncology
Year Founded
First Award
Latest Award
Program Status
Popularity Index
Is this YOUR Company?
Ensure accuracy and completeness of YOUR Company Profile by completing the brief Survey Instrument attached
Do you know about this Awardees?
Let us encourage you to provide any data which would enhance the completeness of this firm's profile.

Location Information

1895 Mount Hope Avenue
Rochester, NY 14620
   (585) 271-2700
Location: Single
Congr. District: 25
County: Monroe

Public Profile

With original ties to the University of Rochester and not SBIR involved in some time, Vaccinex, Inc. (NASDAQ: VCNX) is taking a differentiated approach to treating neurodegenerative disease through the inhibition of semaphorin 4D (SEMA4D), a key driver of neuroinflammation. Actively in SBIR In the years following founding of the firm-- but not recently -- the company’s lead drug candidate, pepinemab, blocks SEMA4D and has potential as a disease-modifying treatment for Huntington’s, Alzheimer’s and other neurodegenerative diseases. Beyond neurology, Vaccinex has determined that, in combination with checkpoint inhibitors, pepinemab has potential to increase objective responses in oncology. The company additionally intends to leverage its proprietary drug discovery platform, ActivMAb®, to create opportunities for future pipeline expansion and strategic collaborations.

Extent of SBIR involvement

User Avatar

Synopsis: Awardee Business Condition

Employee Range
Revenue Range
VC funded?
Publicly Traded
Stock Info
IP Holdings

Awards Distribution by Agency

Most Recent SBIR Projects

Year Phase Agency Total Amount
2005 2 NIH $413,049
Project Title: Functional Identification of Cancer Regulators
2005 2 NIH $1,358,678
Project Title: Human Monoclonal Antibodies for Bioterrorism Defense
2005 2 NIH $599,735
Project Title: New Target Antigens for Prostate Cancer Immunotherapy
2004 1 NIH $217,632
Project Title: Monoclonal Antibody Therapy to Combat Osteoporosis
2004 2 NIH $433,400
Project Title: A Method to identify upstream regulators of oncogenes

Key People / Management

  Maurice Zauderer -- President

  Melinda A Borrello

  Deborah Helleson -- Vice President of Business Development / Consultant

  R Stan Holland -- Vice President of Finance and CFO

  John E Leonard -- SVP Development

  Shaun C Martin -- Director, Business Development

  Eric C Milner

  Mark J Parish

  Ernest S Smith -- Vice President of Research and CSO

  Raymond E Watkins -- Vice President of Operations

Company News

There are no news available.